Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Targeted therapy shows promise against KRAS-driven metastatic pancreatic cancer

An investigational targeted therapy designed to block one of the most common genetic drivers of pancreatic cancer has shown promising early results when combined with standard first-line chemotherapy, according to research presented today at the ESMO Gastrointestinal Cancers Congress 2026.

3 Jul 2026

Melatonin may safely reduce chronic musculoskeletal pain, study finds

A sleep supplement widely used to treat insomnia could help reduce reliance on some of the most common and potentially harmful pain medications, new research from the University of Sydney suggests.

30 Jun 2026

Semaglutide approval drove a surge in GLP-1 poison center exposures

Following semaglutide's approval, poison center reports of GLP-1 RA exposures doubled, revealing critical trends in patient safety and healthcare utilization.

26 Jun 2026

Hyperemesis gravidarum increases risks for pregnancy and birth complications

Pregnant women with a severe form of nausea face increased risks for several pregnancy and birth complications, according to a new Stanford Medicine study of 2.5 million California births.

22 Jun 2026

Researchers uncover genetic cause of spontaneous spinal CSF leaks

Researchers at Cedars-Sinai Health Sciences University and Johns Hopkins University have identified genetic mutations that may explain why some people develop a spontaneous cerebrospinal fluid (CSF) leak in the spine.

17 Jun 2026

Study reveals frequent stop-and-start patterns with GLP-1 drugs

People prescribed GLP-1 medications are more likely to start-and-stop than most people assume, according to a study being presented Sunday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

Parkinson's drug may ease anhedonia in treatment-resistant depression

For many people who suffer from depression, the condition is not just about feeling down, but also about a loss of motivation and difficulty finding pleasure in activities they used to enjoy.

12 Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

11 Jun 2026

Apitegromab helps tirzepatide users lose fat while preserving lean mass

A phase 2 trial found that apitegromab plus tirzepatide reduced lean body mass loss by 1.9 kg compared with tirzepatide plus placebo after 24 weeks, while overall weight loss remained similar.

9 Jun 2026

Obesity drug mazdutide reduces weight and waist size in major trial

Once-weekly 9 mg mazdutide produced clinically meaningful weight loss in Chinese adults with obesity, reducing body weight by 16.65% after 60 weeks versus 1.50% with placebo. The phase 3 GLORY-2 trial also found improvements in waist circumference, systolic blood pressure, and lipid markers, but gastrointestinal adverse events were common.

9 Jun 2026

GLP-1 users say the drugs quiet food noise but do not replace lifestyle change

A qualitative study of 30 US adults found that GLP-1 receptor agonists often reduced “food noise,” psychological hunger, and appetite, helping patients feel more able to make deliberate lifestyle changes.

8 Jun 2026

Weight loss drugs could widen health inequalities without nutritional support

Drugs such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro) are transforming obesity treatment, but without affordable, healthy food and appropriate support, they could widen health inequalities in the UK, according to researchers at UCL and the University of Cambridge.

1 Jun 2026

Novel PRRT approach shows promise in advanced neuroendocrine tumors

A new type of peptide receptor radionuclide therapy (PRRT) appears to be safe in metastatic neuroendocrine tumor patients who have exhausted conventional treatment options.

31 May 2026

Daraxonrasib significantly extends survival in metastatic pancreatic cancer

At the ASCO annual meeting, Dana-Farber's Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

31 May 2026

Climate change could expand chikungunya into temperate regions worldwide

Chikungunya ('to become contorted' in the Kimakonde language, named after the characteristic joint ache) is classified as one of the neglected tropical diseases by the World Health Organization.

27 May 2026

Ongoing nausea in pregnancy may flag anxiety and depression risk

Persistent or severe nausea during pregnancy was linked to higher maternal anxiety and depressive symptoms across gestation. The study found little consistent evidence that nausea worsened most perinatal outcomes, suggesting it may serve mainly as a clinical warning sign for psychological burden.

25 May 2026

Semaglutide helps patients who gain weight after bariatric surgery

New UCL research supports use of the weight loss drug semaglutide for patients who do not get enough benefit from bariatric surgery.

22 May 2026

Oral AD109 improves sleep apnea severity but tolerability remains a challenge

AD109, an investigational once-daily oral combination of aroxybutynin and atomoxetine, significantly improved airway obstruction and oxygenation in adults with mild-to-severe obstructive sleep apnea who could not use PAP therapy. However, symptom improvements did not clearly differ from placebo, and about one in five AD109 recipients discontinued treatment due to adverse events.

21 May 2026

GLP-1 drugs may help curb addiction by targeting reward pathways

GLP-1 receptor agonists, already used for Type 2 diabetes and obesity, show promise in reducing alcohol and drug-seeking behaviors through central reward and dopamine-related pathways. Most evidence remains preclinical, with limited early human data, so larger clinical trials are needed before these drugs can be recommended for addiction treatment.

21 May 2026

Vitamin D deficiency linked to higher postoperative breast cancer pain

Vitamin D deficiency is associated with more moderate to severe pain following breast cancer surgery and an increased consumption of opioid drugs, finds research published online in the journal Regional Anesthesia & Pain Medicine.

19 May 2026